-
Wildland Fire Fighter Refuses to Allow Diagnosis to Define His Life
When Tyler Long was diagnosed with facioscapulohumeral muscular dystrophy (FSHD) during his senior year of
-
Sarepta plans to seek full FDA approval of 2 Duchenne treatments
Sarepta Therapeutics plans to ask the U.S. Food and Drug Administration (FDA) to grant full
-
PPMD Provides $250,000 in Funding to Secretome Therapeutics Through PPMD Venture Pathways Program to Support Development of Cardiac Cell Therapy
PPMD and Secretome Therapeutics (Secretome) are excited to announce that PPMD has provided $250,000 in
-
When it comes to rare disease advocacy, just keep showing up
According to the EveryLife Foundation for Rare Diseases, more than 30 million Americans live with
-
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval
Dyne Therapeutics is advancing its investigational exon-skipping therapy zeleciment rostudirsen (z-rostudirsen), formerly known as DYNE-251,
-
MDA 2026: This year’s MDA meeting provided a glimpse into the future
Muscular Dystrophy News Today is wrapping up coverage of the 2026 Muscular Dystrophy Association (MDA)
-
How to Make Vocational Training Affordable
There are many reasons a person with a disability might choose vocational training. One prominent
-
I’m thankful for a big family that gives my DMD sons a full social life
The comment comes in many forms: “I don’t know how you do it.” “You have
-
17-year-old advocate shares her NMOSD story to raise awareness
In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led
-
MDA 2026: ‘Body of evidence for Elevidys continues to grow’
Boys with Duchenne muscular dystrophy (DMD) who received Sarepta Therapeutics’ gene therapy Elevidys (delandistrogene moxeparvovec-rokl)
